| Stage | RHI | % of rev | KELYB | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.4B | 100.00% | $1.0B | 100.00% | RHI ×1.31 |
| Gross profit | $532M | 39.14% | $212M | 20.42% | RHI +18.7pp |
| Operating income | $73M | 5.34% | $16M | 1.55% | RHI +3.8pp |
| Pre-tax income | $75M | 5.49% | $14M | 1.39% | RHI +4.1pp |
| Net income | $50M | 3.67% | $11M | 1.10% | RHI +2.6pp |
| Stage | RHI | KELYB | Gap · A − B |
|---|---|---|---|
| Revenue | $1.4B100.00% | $1.0B100.00% | RHI ×1.31 |
| Gross profit | 39.14%$532M | 20.42%$212M | RHI +18.7pp |
| Operating income | 5.34%$73M | 1.55%$16M | RHI +3.8pp |
| Pre-tax income | 5.49%$75M | 1.39%$14M | RHI +4.1pp |
| Net income |
| 3.67%$50M |
| 1.10%$11M |
| RHI +2.6pp |
No disclosed counterparties: KELYB.
None